"Indonesia Pharmaceuticals & Healthcare Report Q3 2013" Is Now Available at Fast Market Research
Theoretically, considerable opportunities for pharmaceutical manufacturers exist in relation to the Indonesian pharmaceutical market. Demand for medicines will continue to be supported by the country's large population, the rollout of the universal healthcare programme in 2014 (with the ultimate aim to cover all Indonesians by 2019) and the expansion of healthcare services. However, Indonesia will remain a risky operating environment, with market access hampered by a range of intellectual property barriers and the government's biased stance against foreign companies.
View full press release